Application of 18FFDG PETCT in nasopharyngeal carcinoma

doi:10.3760/cma.j.issn.1673422X.2016.08.013

Abstract

Abstract: 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) is the integration of functional imaging and anatomic information, which is found to be particularly valuable in TNM staging, tumor volume delineating, posttreatment assessment, identification of recurrent and residual nasopharyngeal carcinoma (NPC). The combination of 18F-FDG PET-CT with other image technologies, different tracer agents, and specific molecular biomarkers can improve the application value of 18F-FDG PET-CT in NPC.

Key words: Nasopharyngeal neoplasms, Radiotherapy, Fluorodeoxyglucose F18, Positronemission tomography

Luo Li, Shen Qun, Xi Xuping, Liu Feng, Xiao Feng.. Application of 18FFDG PETCT in nasopharyngeal carcinoma[J]. Journal of International Oncology, 2016, 43(8): 615-618.

References

［1］ Leclerc M, Lartigau E, Lacornerie T, et al. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy［J］. Radiother Oncol, 2015, 116(1): 87-93. DOI: 10.1016/j.radonc.2015.06.007. ［2］ Wei J, Pei S, Zhu X. Comparison of (18)F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: a meta-analysis［J］. Oral Oncol, 2016, 52(52): 11-17. DOI: 10.1016/j.oraloncology.2015.10.010. ［3］ Gordin A, Golz A, Daitzchman M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management［J］. Int J Radiat Oncol Biol Phys, 2007, 68(2): 370-376. DOI: 10.1016/j.ijrobp.2006.12.028. ［4］ Anderson CM, Chang T, Graham MM, et al. Change of maximum standardized uptake value slope in dynamic triphasic ［18F］ fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in headandneck squamous cell carcinoma: a prospective trial［J］. Int J Radiat Oncol Biol Phys, 2015, 91(3): 472-479. DOI: 10.1016/j.ijrobp.2014.11.002. ［5］ Chan WK, Mak HK, Huang B, et al. Nasopharyngeal carcinoma: relationship between 18F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification［J］. Nucl Med Commun, 2010, 31(3): 206-210. DOI: 10.1097/MNM.0b013e328333e3ef. ［6］ Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging workup［J］. Eur J Nucl Med Mol Imaging, 2009, 36(1): 12-22. DOI: 10.1007/s00259-008-0918-7. ［7］ Vellayappan BA, Soon YY, Earnest A, et al. Accuracy of (18)F-flurodeoxyglucosepositron emission tomography/computed tomography in the staging of newly diagnosed nasopharyngeal carcinoma: a syste-matic review and metaanalysis［J］. Radiol Oncol, 2014, 48(4): 331-338. DOI: 10.2478/raon-2014-0011. ［8］林勤, 李夷民, 周原, 等. 18F-FDG PET/CT在鼻咽癌颈部淋巴结转移分期中的作用［J］. 中华核医学与分子影像杂志, 2012, 32(6): 418-421. DOI: 10.3760/cma.j.issn.20952848.2012.06.004. ［9］ Chang MC, Chen JH, Liang JA, et al. Accuracy of wholebody FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and metaanalysis［J］. Eur J Radiol, 2013, 82(2): 366-373. DOI: 10.1016/j.ejrad.2012.06.031. ［10］ Tang LQ, Chen QY, Fan W, et al. Prospective study of tailoring wholebody dualmodality ［18F］ fluorodeoxyglucose positron emission tomography/computed tomography with plasma EpsteinBarr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging［J］. J Clin Oncol, 2013, 31(23): 2861-2869. DOI: 10.1200/JCO.2012.46.0816. ［11］ Law A, Peters LJ, Dutu G, et al. The utility of PET/CT in staging and assessment of treatment response of nasopharyngeal cancer［J］. J Med Imaging Radiat Oncol, 2011, 55(2): 199-205. DOI: 10.1111/j.17549485.2011.02252.x. ［12］林勤, 吴华, 朱鹭超, 等. FDG PET-CT与MRI在鼻咽癌原发灶靶区勾画中的对比研究［J］. 中华放射肿瘤学杂志, 2012, 21(6): 492-495. DOI: 10.3760/cma.j.issn.10044221.2012.06.003. ［13］ Delouya G, Igidbashian L, Houle A, et al. 18F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer［J］. Radiother Oncol, 2011, 101(3): 362-368. DOI: 10.1016/j.radonc.2011.07.025. ［14］ Hung GU, Wu IS, Lee HS, et al. Primary tumor volume measured by FDG PET and CT in nasopharyngeal carcinoma［J］. Clin Nucl Med, 2011, 36(6): 447-451. DOI: 10.1097/RLU.0b013e31821738b8. ［15］邓翀, 林勤, 石丽婉, 等. 18F-FDG PET/CT勾画鼻咽癌原发肿瘤体积最适阈值的研究［J］. 中华放射医学与防护杂志, 2014, 34(7): 530-534. DOI: 10.3760/cma.j.issn.02545098.2014.07.013. ［16］ Meijer G, Steenhuijsen J, Bal M, et al. Dose painting by contours versus dose painting by numbers for stage Ⅱ/Ⅲ lung cancer: practical implications of using a broad or sharp brush［J］. Radiother Oncol, 2011, 100(3): 396-401. DOI: 10.1016/j.radonc.2011.08.048. ［17］ Duprez F, De Neve W, De Gersem W, et al. Adaptive dose painting by numbers for headand-neck cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 80(4): 1045-1055. DOI: 10.1016/j.ijrobp.2010.03.028. ［18］ Chan SC, Chang JT, Lin CY, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification［J］. Nucl Med Commun, 2011, 32(11): 989-996. DOI: 10.1097/MNM.0b013e3283495662. ［19］ Liu WS, Wu MF, Tseng HC, et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensitymodulated radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2012, 82(2): 561-566. DOI: 10.1016/j.ijrobp.2010.11.055. ［20］ Hung TM, Wang HM, Kang CJ, et al. Pretreatment (18)FFDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma［J］. Oral Oncol, 2013, 49(2): 169-174. DOI: 10.1016/j.oraloncology.2012.08.011. ［21］ Chan SC, Kuo WH, Wang HM, et al. Prognostic implications of posttherapy (18)FFDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy［J］. Ann Nucl Med, 2013, 27(8): 710-719. DOI: 10.1007/s12149-013-0736-2. ［22］ Chan SC, Hsu CL, Yen TC, et al. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma［J］. Oral Oncol, 2013, 49(1): 71-78. DOI: 10.1016/j.oraloncology.2012.07.016. ［23］ Moon SH, Choi JY, Lee HJ, et al. Prognostic value of volumebased positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy［J］. Clin Exp Otorhinolaryngol, 2015, 8(2): 142-148. DOI: 10.3342/ceo.2015.8.2.142. ［24］ Shen G, Zhou L, Jia Z, et al. Metaanalysis of PET/CT for diagnosis of residual/recurrent nasopharyngeal carcinoma［J］. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2015, 29(1): 61-67. ［25］ Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review［J］. Radiother Oncol, 2007, 85(3): 327-335. DOI: 10.1016/j.radonc.2007.11.002.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[7]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[8]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[11]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[12]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[13]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[14]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[15]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.